Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Than 60 Genetic Cancer Tests Have Become Available In Past Two Years

This article was originally published in The Gray Sheet

Executive Summary

Breast cancer tests are the most common among the new genetic tests to emerge since 2011, an Agency for Healthcare Research and Quality report finds.

You may also be interested in...



CMS Will Weigh Three New Tech Assessments On Genetic Testing For Cancer

Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.

CMS Issues List Of Potential National Coverage Determination Topics

Most of the 33 items or services in the list have implications for manufacturers of medical devices, combination products or diagnostics.

AHRQ Finds Breast Cancer Tops List Of New Genetic Oncology Tests

The Agency for Healthcare Research and Quality has identified 38 new genetic tests for cancer that have entered U.S. or overseas markets since 2006, with breast cancer the most common disease target.

Topics

UsernamePublicRestriction

Register

MT032346

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel